Pharmaceutical Product Development, LLC (PPD) is a global contract research organization (CRO) and will conduct the studies in the US and Europe.
As part of its agreement, PPD Biotech – the CRO’s dedicated service for biotech and small- to mid-sized pharma – will manage the cancer vaccine trials.
Daniel Burch, MD, vice president and global medical officer for PPD Biotech told us the company will support Treos Bio with a range of clinical and laboratory services.
London-headquartered Treos Bio is developing precision peptide cancer vaccines and companion diagnostics. It has completed preclinical development for six additional cancer vaccine products in addition to the colorectal cancer vaccine.
According to the company, the precision vaccines are being developed to treat breast cancer, lung cancer, ovarian cancer, glioma, melanoma and leukemia.